Table 1.
Anthropometric and perioperative data for the 33 study participants (mean(SD))
| ORP (n = 9) | RALP (n = 24) | Total (n = 33) | |
|---|---|---|---|
| Anthropometric data |
|
|
|
| Age (yr) |
60 (7) |
63 (6) |
62 (6) |
| Height (m) |
1.76 (0.07) |
1.75 (0.05) |
1.75 (0.06) |
| Weight (kg) |
92 (12) |
83 (10) |
86 (11) |
| BMI (kg.m-2) |
29.6 (4.5) |
27.3 (3.0) |
27.9 (3.6) |
| Preoperative factors |
|
|
|
| PSA (ng/mL) |
5.8 (4.2) |
5.0 (2.1) |
5.2 (2.8) |
| Preoperative Gleason score |
|
|
|
| 3 + 3 |
1 (11%) |
5 (21%) |
6 (18%) |
| 3 + 4 |
5 (56%) |
16 (67%) |
21 (64%) |
| 4 + 3 |
3 (33%) |
2 (9%) |
5 (15%) |
| 4 + 4 |
0 (0%) |
1 (4%) |
1 (3%) |
| Clinical tumour stage |
|
|
|
| cT1 |
4 (44%) |
13 (54%) |
17 (52%) |
| cT2 |
5 (56%) |
11 (46%) |
16 (48%) |
| cT3 |
0 (0%) |
0 (0%) |
0 (0%) |
| cT4 |
0 (0%) |
0 (0%) |
0 (0%) |
| Prostate volume (cc) |
40.2 (13.4) |
41.2 (12.5) |
40.9 (12.6) |
| Intraoperative factors |
|
|
|
| Nerve sparing |
|
|
|
| None |
3 (33%) |
3 (13%) |
6 (18%) |
| One bundle |
2 (22%) |
2 (9%) |
4 (12%) |
| Two bundles |
4 (44%) |
19 (79%) |
23 (70%) |
| Pelvic lymph node dissection |
7 (78%) |
2 (9%)a |
9 (27%) |
| Bladder neck preservation |
0 (0%) |
23 (96%)a |
23 (70%) |
| Postoperative factors |
|
|
|
| Postoperative Gleason score |
|
|
|
| 3 + 3 |
1 (11%) |
3 (13%) |
4 (12%) |
| 3 + 4 |
6 (67%) |
16 (67%) |
22 (67%) |
| 4 + 3 |
2 (22%) |
5 (21%) |
7 (21%) |
| 4 + 4 |
0 (0%) |
0 (0%) |
0 (0%) |
| Pathological tumour stage |
|
|
|
| pT2 |
6 (67%) |
18 (75%) |
24 (73%) |
| pT3 |
3 (33%) |
6 (25%) |
9 (27%) |
| pT4 |
0 (0%) |
0 (0%) |
0 (0%) |
| Positive lymph nodes |
1/7 (14%) |
0/2 (0%) |
1/9 (11%) |
| Positive margins |
2 (22%) |
2 (9%) |
4 (12%) |
| Duration of postoperative hospital stay (d) |
2.9 (0.3) |
2.0 (0.2)a |
2.3 (0.5) |
| Duration of postoperative catheterization (d) |
10.2 (3.0) |
8.4 (1.6) |
8.9 (2.2) |
| Anastomic structure | 0 (0%) | 1 (4%) | 1 (3%) |
ORP, Open retropubic prostatectomy; RALP, Robotic-assisted laparoscopic prostatectomy; BMI, Body mass index; PSA, Prostate specific antigen.
a: p < 0.001 vs ORP.